N-Acetylcysteine reduced ischemia and reperfusion damage associated with steatohepatitis in mice
Cayuela, Natalie Chaves
Koike, Marcia Kiyomi
Jacysyn, Jacqueline de Fátima
Cerqueira, Anderson Romério Azevedo
Costa, Soraia Katia Pereira
Diniz Junior, José Antônio Picanço
Utivama, Edivaldo Massazo
Montero, Edna Frasson de Souza
N-acetylcysteine (NAC) is a pharmacological alternative with great potential for reducing the deleterious effects of surgical procedures on patients with steatohepatitis. We evaluated the effect of NAC on hepatic ischemia/reperfusion (I/R) injury in C57BL/6J mice, 8 weeks-old, weighing 25–30 g, with steatohepatitis induced by a methionine- and choline-deficient (MCD) diet. Groups: MCD group (steatohepatitis), MCD-I/R group (steatohepatitis plus 30 min of 70% liver ischemia and 24 h of reperfusion), MCD-I/R+NAC group (same as MCD-I/R group plus 150 mg/kg NAC 15 min before ischemia), and control group (normal AIN-93M diet). Liver enzymes and histopathology; nitrite and TBARS (thiobarbituric acid reactive substances) levels; pro-inflammatory cytokines; antioxidants enzymes; Nrf2 (nuclear factor erythroid-2-related factor 2) expression; and apoptosis were evaluated. In the group treated with NAC, reductions in inflammatory infiltration; AST (aspartate aminotransferase), nitrite, and TBARS levels; GPx (gutathione peroxidase) activity; cytokines synthesis; and number of apoptotic cells were observed while the GR (glutathione reductase) activity was increased. No differences were observed in Nfr2 expression or in SOD (superoxide dismutase), CAT (catalase), and GST (glutathione S-transferase) activities. Thus, it may be concluded that NAC exerts beneficial effects on mice livers with steatohepatitis submitted to I/R by reducing oxidative stress, inflammatory response, and cell death.
xmlui.dri2xhtml.METS-1.0.item-citationCAYUELA, Natalie Chaves et al. N-Acetylcysteine reduced ischemia and reperfusion damage associated with steatohepatitis in mice. International Journal of Molecular Sciences, v. 21, n. 11, p. 1-19, 2020.
xmlui.dri2xhtml.METS-1.0.item-decsPrimaryFígado Gorduroso / Diagnóstico
Fígado Gorduroso / tratamento farmacológico
Acetilcisteína / uso terapêutico
Acetilcisteína / farmacologia